(Poly)phenols in Human Breast Milk and their health benefits for the newborn

Diogo Carregosa[1], Inês P. Silva[1], Carolina Teixeira[1], Mariana Baltazar[1], Rocio García-Villalba[2], Filipa Soares Vieira[3], Mónica Marçal[1,3], Madalena Tuna[3,4], Cláudia N. Santos[1]

[1] iNOVA4Health, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 1169-056 Lisboa, Portugal.

[2] Laboratory of Food & Health, Research Group on Quality, Safety, and Bioactivity of Plant Foods, CEBAS-CSIC, Murcia, Spain.

[3] Hospital de São Francisco Xavier - Centro Hospitalar de Lisboa ocidental E.P.E.

[4] CHRC, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 1169-056 Lisboa, Portugal.

Corresponding author: claudia.nunes.santos@nms.unl.pt

Abbreviations used: BM, breast milk; BSID, Bayley Scales of Infant Development; DOPAC, 2-(3,4-dihydroxyphenyl)acetic acid; EHC, enterohepatic circulation; FRAP, ferric reducing antioxidant power; LMW, low molecular weight; MDI, Mental Developmental Index; OAT, organic acid transporter; ORAC, oxygen radical absorbance capacity; PDI, Psychomotor Development Index; PLS-3, Preschool Language Scale-3; SC, systemic circulation; SPE, solid phase extraction; TEAC, trolox equivalent antioxidant capacity; TRAP, total reactive antioxidant potential

Abstract

Human breast milk is the first food source available to newborns and is responsible for healthy growth and development during the first months of life. Human breast milk contains vitamins, hormones, cytokines, microbiota, and immune cells that are responsible for such healthy conditions. Nonetheless, knowledge of the vast array of molecules present in human breast milk and their potential health effects is still lacking. The effects of mothers' diets on the molecules present in human breast milk are also generally unknown. The health benefits of (poly)phenols have been largely increasing but their presence in breast milk has been put largely aside. The impact of the mother's diet in the presence and quantification of these molecules in milk has also been overlooked. Above all, the potential benefits of (poly)phenols for newborns are just a vast emptiness of what is known about (poly)phenol research.

Keywords: Polyphenols, Breast Milk, Newborn, Metabolites, Concentrations

1. Introduction

Human breast milk is produced by the mammary gland and is essential for the healthy growth and development of newborns. Human breast milk is characterized by a huge complexity and diversity of components, including nutrients, such as proteins, carbohydrates, and lipids (1); bioactive components, such as immunoglobulins, stem cells, cytokines, hormones, growth factors, and phytochemicals (2); and a vast array of bacteria, such as *Staphylococcus, Streptococcus, Bifidobacterium, Lactobacillus, and Clostridium* cluster XIVa–XIVb (3). This chemical and biological diversity of agents in its composition provides the infant with well-balanced nutrition and protection against potential infectious pathogens as the infant immune system develops (4). For these reasons and for optimal health and growth, the World Health Organization (5) recommends that infants be exclusively breastfed for the first six months of life, and that breastfeeding continues to be an

important part of the diet until the infant is at least two years old. In addition to nutrients, vitamins, cells, and other compounds beneficial for health, it is not surprising that breast milk also contains some undesirable molecules, for example xenobiotics. Environmental xenobiotics in air, water and soil are absorbed by organisms through ingestion, inhalation or dermal absorption and enter the human food chain and often can be found in milk samples (6).

Human breast milk is a dynamic fluid that arises from the lactation process and develops to the different newborn needs. Breast milk can be classified into different stages based on its chemical composition. The first stage is pre-colostrum. This occurs as result of the process of lactogenesis that starts as early as the second trimester of pregnancy, the 16th week of pregnancy, due to the increased levels of estrogen and progesterone in the circulation (7). From day 5 up until day 7 after birth, colostrum is secreted and has a sticky consistency of yellow color given by the presence of carotenes from dietary intake. Colostrum is characterized by its nutritional, immunological and growth functions. The third stage is the transition milk produced between days 4 and 15 after childbirth, which shows a white color due to the emulsification of fats and the strong presence of calcium caseinate (7). Finally, mature milk, is produced from the 15th postpartum day looking like a thinner and diluted milk (8). During the different maturation stages of human breast milk, a high degree of interindividual differences can be expected in milk that may arise from differences in milk production and possible differences in transport of the molecules and other milk components like cells from blood to milk. Moreover, these differences are expected to be at least partially explained by a different dietary intake of the mother. However, we still lack knowledge on how diets like the Mediterranean diet, or vegetarian diets, rich in phytochemicals, might influence on the content of these compounds or their metabolites in human breast milk and how these might impact the health and development of the newborn.

Thousands of different dietary phytochemicals have been identified in human breast milk, of which carotenoids and (poly)phenols (9), represent by far the largest groups (10,11). In

this study, we focused on the role of (poly)phenols such as phenolic acids, flavonoids,

stilbenes, coumarins, lignans, and tannins (Figure 1) and their host and microbial

metabolites for their well-documented protective and health-promoting properties, which

are less understood compared to carotenoids (12).

(Poly)phenols, a class of phytochemicals containing at least one phenolic ring, that are

present in large quantities in fruits and vegetables like soybeans, cocoa beans, oranges and

berries, as well as tea and coffee (13). They are believed to have health benefits, including

protection against oxidative stress and inflammation, and may decrease the risk of chronic

and degenerative diseases such as neurodegenerative disorders, obesity, cancer, and

diabetes (14–18). They are classified in flavonoids and non-flavonoids where the latter

include lignans, stilbenes, coumarins, tannins and simple phenolics/phenolic acids (Figure

1). Flavonoids represent the vast majority of (poly)phenols present in a fruit- and vegetable-

rich diet, and include different subclasses such as: flavones, isoflavones, flavan-3-ols,

flavonols, flavanones and anthocyanins. These (poly)phenols have demonstrated biological

activities, including antioxidant and anti-inflammatory activities, consistent with the promotion

of vascular health, bone health, and cognitive function (14,16,19). It has been demonstrated

that the biological activities of all these phenolic compounds may be mediated by their

metabolites which are produced *in vivo* (host and microbial metabolites), as in the case of

urolithins, the ellagic acid microbial metabolites (20) and phenolic acids the flavonoid

microbial metabolites (16,21).

Flavonoids

Flavone

Flavonol

Flavanone

Isoflavones

Anthocyanin

Flavan-3-ols

Lignans

Stilbenes

Coumarins

Tannins

Ellagic acid and microbiota metabolites

Ellagic acid

Urolithins

Phenolics, phenolic acids and microbiota metabolites

Phenol

Benzaldehyde

Benzoic acid

Phenylacetic acids

3-(phenyl)propanoic acids

Cinnamic acids

5-(phenyl)-γ-valerolactone

99   Figure 1 – Chemical structures of common dietary (poly)phenols and microbiota metabolites.

100   In the figure are represented: flavonoids, lignans, stilbenes, coumarins, tannins, ellagic acids

101   and the microbiota derived metabolites urolithins and phenolics/phenolic acids and the

102   microbiota metabolite like 5-(phenyl)-γ-valerolactones.

103   2. Absorption, metabolism, and distribution of (poly)phenols

Owing the wide variety of (poly)phenols, like flavonoids, phenolic acids, ellagic acids, among

others, bioavailability varies a lot from one family to another. Some flavonoids like

anthocyanins, isoflavones such as genistein and daidzein and the flavanol quercetin can be

partially absorbed as early as in the stomach(22–25). However, most flavonoids are found in

foods conjugated with sugars, esterified with organic acids, and polymerized, which

decreases their absorption in the stomach, reaching the small intestine. In the intestine intact

glycosides may undergo the action of lactase phloridzin hydrolase or cytosolic β-glucosidase

breaking the sugar bond and releasing the respective aglycones which are subsequently

absorbed. (Poly)phenols, namely flavonoids and ellagic acids that are not absorbed in the

small intestine reach the colon where they are transformed by the gut microbiota (Figure 2).

In the case of flavonoids, they undergo catabolic reaction by the gut microbiota producing

the low molecular weight phenolic metabolites also known by simple phenolics and phenolic

acids, some of which common to those found in plants and already absorbed in initial

phases of digestion, like benzoic acids (13,26). In fact, simple phenolics and phenolic acids

present in the gut might result from two distinct pathways i) directly from the intake of fruits

and vegetables or ii) the result of gut microbiota catabolism of flavonoids. Meanwhile,

several (poly)phenols metabolites can only be produced by gut microbiota. This is the case

of equol, produced exclusively by gut microbiota catabolism of the isoflavone daidzein,

enterodiol and enterolactone, produced by catabolism of lignans, 5-(phenyl)-γ-valerolactones

characteristic microbial metabolites of flavan-3-ols or urolithins the gut microbiota

metabolites of ellagitannins and ellagic acid (27–29). In the case of equol and urolithins the

presence of specific bacteria in the microbiota of the volunteers allowed to classify them in

different metabotypes (20). For equol the two metabotypes differentiate equol-producers and

equol-non producers. Meanwhile for urolithins three different urolithin metabotypes exist

according to the capability of gut microbiota of the host to catabolize ellagic acid. These are

metabotype A: producers of urolithin A; metabotype B: producers of isourolithin A and/or

urolithin B, and metabotype 0: non producers of urolithins (20,30).

Directly after their absorption in the small intestine or in the colon, (poly)phenolsand their gut

microbiota catabolites are extensively metabolized at both the intestinal and hepatic levels.

Independently of the type of (poly)phenol, all undergo phase I and II metabolic reactions

mediated by sulfotransferases, methyltransferases and glucuronyltransferases. Once in

portal circulation, (poly)phenols metabolites travel into the liver where they undergo further

phase I and II metabolic reactions. From the liver, (poly)phenols or their metabolites may

reenter the intestine through bile salts and the enterohepatic circulation (EHC) or enter

systemic circulation (Figure 2). In circulation, (poly)phenols metabolites spread across the

different organs and tissues to exert their potential biological effects or are retrained in the

kidneys and eliminated through urine. Importantly, several phenolic metabolites resulting

from dietary intake or gut microbiota catabolism of flavonoids are also produced by some

endogenous pathways. Some examples of molecules shared between pathways may

include hippuric acid, homovanillic acid and 3',4'-dihydroxyphenylacetic acid.

In lactating women, different (poly)phenols and their metabolites, mainly flavonoids, phenolic

acids and ellagic acid and urolithin metabolites, have been detected in breast milk, as will be

discussed ahead. These are expected to travel from blood circulation reaching the mammary

glands (Figure 2), although the mechanism of transport has not been fully characterized.

(Poly)phenols or their metabolites present in breast milk will start a new cycle of digestion as

they will be ingested by the newborn infant. Importantly due to early stages of gut microbiota

development in the infant, the amount of (poly)phenol metabolism expected in the infant is

limited in comparison with the mother, but much about the infant microbiota capability to

metabolize (poly)phenols is still unknown.

Figure 2- (Poly)phenol journey from dietary intake to breast milk in mothers and delivery the
infant. (Poly)phenols are up taken from the diet reaching the gut. In the mother's gut these
(poly)phenols are absorbed and potentially modified by phase I and II metabolic reactions.
Meanwhile (poly)phenols may be catabolized by gut microbiota into low molecular weight
phenolics that are also up taken and undergo phase I and II metabolic reactions. All these
compounds reach the liver and are released into circulation where they may reach breast
milk. EHC – enterohepatic circulation; SC – systemic circulation; BM – breast milk.

3. (Poly)phenolic content in Human Breast Milk

3.1 Search strategy

First, we searched the most well-known metabolomic and/or (poly)phenolic databases
regarding presence of (poly)phenols in breast milk, e.g., HMDB, phenol-explorer, phyto-hub,
metabolomics workbench, among others(31–33). Overall, only HMDB reported detection and
quantification of (poly)phenols in human breast milk (34). A total of 122 metabolites have
been detected in human breast milk according to HMDB, mainly including amino acids,
short-chain-fatty acids, sugars, and carotenoids. From this list the only (poly)phenol
metabolite reported was hippuric acid (34). Unfortunately, hippuric acid is also common to
endogenous pathways and is difficult to pinpoint its origin (endogenous versus dietary).

Afterwards, we searched PubMed for articles containing the words: "human milk" or "human

breast milk" and "polyphenol" or "flavonoid". In total, we found 63 articles of which 2 were

excluded due to duplication. Furthermore, 7 additional records were added since were found

through other meanings (e.g., through in-text citing references). From the 68 records, 4 have

been excluded since were not available in English. Furthermore, 45 articles have been

excluded since they did not perform detection and/or quantification of (poly)phenols or

human breast milk has not been used. (Figure 3).

Figure 3. Search strategy for the literature review and revision process

3.2 Records reporting (poly)phenol quantification

From the list of records found, 19 have detected and quantified dietary (poly)phenols and/or

metabolites in human breast milk. Of these, 12 have quantified (poly)phenols and/or

metabolites from dietary intervention studies (Table 1) while 7 have quantified (poly)phenols

and/or metabolites in free-living subjects (Table 2). Meanwhile, 15 of these 19 studies have

quantified flavonoids, 4 have quantified ellagic acid or urolithins metabolites, and 6 studies

have reported the quantification of low molecular weight phenolics (phenolic acids or simple

phenols), see Table 1 and Table 2. Noteworthy 4 of the 7 studies quantifying (poly)phenols

and/or metabolites in free-living subjects have included food-frequency questionaries to the

participants of the study to monitor their diet.

Several studies have shown the presence of isoflavones, mainly daidzein and genistein in

human breast milk after dietary interventions using isoflavone rich foods like soybean milk

(35,36), and roasted soybean (37–39). Meanwhile other flavonoids like flavan-3-ols and their

microbial metabolites, 5-(phenyl)-γ-valerolactones were quantified in human breast milk after

consumption of dark chocolate (40).Meanwhile, flavanones were detected after consumption

of grapefruit juice (41), flavonols after onion soup intake (42) and the ellagitannin microbial

metabolites, urolithins, after nuts and pomegranate consumption (20,43). In other studies,

several (poly)phenol compounds, including different families of flavonoids, microbial

metabolites, and phenolic acids, were tentatively identified in breast milk after consumption

of red raspberry (44), and several in free-living conditions summarized in Table 2.

As previously described, breast milk composition evolves over time while the newborn

matures. Most studies have only used matured milk as the sample to detect and quantify

(poly)phenols and/or metabolites (Table 1 and Table 2). Meanwhile, transition milk has only

been used in four studies and colostrum in three studies, all with free-living mothers.

Notably, the three studies reporting (poly)phenol and/or metabolites quantification in

colostrum have also used transitional milk and mature milk as samples.

Khymenets *et al.* was able to quantify some epicatechin phase II conjugates (epicatechin-4-

glucuronide, epicatechin-2-sulfate and epicatechin-3-sulfate) and several gut microbiota

derived metabolites like 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-sulfate and glucuronide

conjugates (40). In this study, participants were in a free-living diet condition and answer to

24-hour dietary recall and food frequency questionnaires showing that the total (poly)phenol

consumption through the diet did not significantly change during the different lactation

periods. However, concentrations of the detected metabolites were very sporadic and varied

significantly only being detected in a limited number of samples across the different lactation

phases. For this reason, the authors were unable to compare the changes in concentrations

amongst the different lactation stages.

Meanwhile, Sánchez-Hernández *et al.*, showed differences in the average amount of total

(poly)phenols present in colostrum, transitional and matured milk, 661, 773 and 652 µg/100

mL respectively, of free-living individuals in comparison with infant formula, 375 µg/100 mL,

(9). Noteworthy, this reflects in general on a 2-fold increase in total (poly)phenol content in

human breast milk in comparison with formula milk (only 375 µg/100 mL), reflecting that

formula milk does not recapitulate complete human breast milk concerning (poly)phenol

content. Regarding the different stages of human breast milk, despite being a non-static fluid

that changes with time, no difference in total (poly)phenol content or antioxidant capacity

was observed among the three different types of milk.

In a different study Song *et al.*, was able to quantify several flavan-3-ols (epicatechin,

epicatechin-gallate and epigallocatechin gallate), flavonols (quercetin and kaempferol) and

flavanones (naringenin and hesperitin) in breast milk samples from free-living mothers at

weeks 1, 4 and 13 postpartum (14). The concentrations of the those (poly)phenols did not

seem to change, independently of the timepoint of collection (week 1, 4 or 13), with the only

exception being kaempferol that significantly increased at week 13. The authors point out

that the levels of flavonoids during the three periods suggest that (poly)phenols in human

milk are generally not affected by lactation stage. Unfortunately, in this study the food intake

of the mothers was not evaluated and thus the estimation of (poly)phenol intake for each

mother was not performed. For this reason, it is possible that some of the variability in

kaempferol concentrations might be due to the food intake of the mother. In fact, from the list

of studies identified, the study by Lu *et al.* was the only that fully characterized and stratified

samples according to the food intake (2). For that maternal intake of plant-based foods and

(poly)phenols was estimated through 3-day dietary records and the use of Phenol-Explorer

database. The study concluded that the intake of plant-based foods significantly affected

phenolic composition in breast milk.

Meanwhile Romasko *et al.* showed that the amount of naringenin in breast milk in free living

mothers with their everyday diet, resulted in an average naringenin concentration in breast

milk of 823.24 nmol/L (41). Upon consumption of red grapefruit juice, rich in naringenin and

naringin (naringenin-7-glucoside) this concentration did not significantly increase at 4 or 12

hours, 908.25 nmol/L ± 676.84 nmol/L, and 868.96 nmol/l ± 665.54 nmol/L, respectively. In

this case, the consumption of a glass of grapefruit juice did not significantly affect naringenin

levels in milk. Eventually the concentrations of naringenin decreased after 48 hours to

673.89 nmol/L. Meanwhile in a study by Jochum *et al.* two different interventions were used

and compared against a control (300 mL water) drink: i) 250 mL of soy drink or ii) 300mL of

decaffeinated black tea (36). Unfortunately, no flavonol was detected before or after the

intervention with black tea. Yet, in the soy drink group, genistein and daidzein were detected,

but only after the intervention.

The changes in values across these studies may be related to several factors. One of the

most important is dietary exposure to different amounts of (poly)phenols and/or foods

containing different/specific (poly)phenols. Dissimilarities in the dietary habits among

different populations could lead to high variability in the results obtained. It is very important

to define dietary habits during lactation to fully understand how these changes in

(poly)phenol and/or metabolites quantification is dependent on the mother's diet. However,

there is still limited information on the relationship between maternal dietary intake and

phenolic content in breast milk. Besides, although the concentration of the compounds is

dependent on the dose ingested by the mother, other regular components of the matrix such

as proteins, lipids and carbohydrates could affect the extraction and detection of these

compounds.

Other important factors that could influence the detection and quantification of (poly)phenols

and/or metabolites in human breast milk could be the kinetic of deposition in milk,

interindividual differences in the metabolism and genetic/physiological factors and/or stability

of (poly)phenols and/or metabolites in breast milk matrix. Although with the available studies,

the time of milk collection has not been demonstrated to be a crucial factor, more studies

with large population are needed to confirm these results. The methodology for the collection

of breast milk samples could also be another critical point. Most of the time the volume of

the milk produced by the mammary glands of the mothers is not measured, so the data

obtained from the milk analysis only provide concentrations and not the total amount

produced, what makes more difficult to compare among studies. Number of volunteers

across the 19 studies herein reported has also shown a significant pitfall on the data

available to researchers and clinicians. Until now only one study has used a sample size

equal to 50 volunteers, while most studies have used sample sizes below 30 volunteers, with

a significant number of studies with a sample size below 10 and some proof-of-concept/case

studies with sample sizes of just one or two individuals. Such sample size, together with the

normal interindividual variability detected in (poly)phenol bioavailability (26,45) clearly makes

it difficult to understand the dynamics of (poly)phenols metabolites in breast milk. Larger

populations are necessary to obtain final conclusions about concentrations of metabolites in

breast milk and factors affecting.

Differences in the methodologies used for the extraction and analysis (identification and

quantification) of these compounds in breast milk also hamper the comparison among

studies.

The complexity of the milk matrix partly explains why the determination of (poly)phenol-

derived metabolites in breast milk has hardly been investigated. Most of the methodologies

are not optimized and validated and the recovery percentages of (poly)phenol metabolites

are usually unknown for the different extraction protocols. Most previous studies have

determined (poly)phenols in human milk after enzymatic hydrolysis (β-glucuronidase and

sulfatase) and subsequent extraction with ethyl acetate (see Table 1 and Table 2). The

enzymatic hydrolysis simplifies the separation and quantification of the major compounds

and provides an idea of the total amount of a specific aglycone (free compound plus

conjugated) but information about the nature of the metabolites available and the amount of

individual conjugated metabolites is lost. Only 5 studies provide information about naturally

occurring metabolites (glucuronides and sulfates) present in breast milk (40,43,44,46,47).

Protein precipitation with acetonitrile or methanol and solid phase extraction (SPE) were also

applied for the extraction of these compounds with and without previous enzymatic

hydrolysis. In some cases, a previous clean up with hexane was applied to defat the

samples and other methods to remove proteins were also used (hydrolysis with pepsin,

salting-out assisted liquid-liquid extraction, precipitation with organic solvents, etc.).

However, little information about recoveries and validation parameters was provided to

evaluate the results and identify the best extraction protocol for each family of compounds.

Only two studies have shown a comprehensive test between the different extraction

methodologies (46,48). The data showed that acetonitrile: formic acid (95:1)

extraction/protein precipitation method was the most effective method to obtain ellagic acid

metabolites in comparison to methanol, hexane and SPE (46). Meanwhile Edyta Nalewajko-

Sieliwoniuk showed that hexane defat followed by acidification and ethyl acetate: acetonitrile

extraction was the most effective method for the extraction of several flavonoids and

phenolic acids (48). Unfortunately, this protocol includes the use of β-glucuronidase and

sulfatases. In general, it seems that ethyl acetate, which is frequently used for isolation of

dietary phenolic compounds, is a good solvent for the extraction of aglycones after

enzymatic hydrolysis. However, when more polar compounds such as glucuronide and

sulfate conjugates are extracted, the recoveries are low and other protocols based of

precipitation of protein with organic solvents or solid phase extraction should be used.

Another question that could affect the extraction and analysis of compounds in the different

studies is the nature of the milk (content of protein and lipids) that could affect the extraction

protocol with the formation of gel aggregates or the precipitation of some compounds.

Besides, the way of quantification is another important question that could influence the

results in the different studies. In most cases the absence of commercial standards forces to

quantify using other available standards, obtaining inaccurate results not comparable among

studies.

3.3 Detected and quantified (poly)phenols in human breast milk

Across the 19 records reporting (poly)phenols and metabolites in human breast milk a total

of 25 flavonoids, 58 low molecular weight phenolics and 9 ellagic acid metabolites were

detected (Figure 4, Table 3-5). The list of flavonoids included the most representative

subfamilies of flavonoids: anthocyanins, flavonols, flavan-3-ols, isoflavones and flavanones

(Table 3, Figure 4). Interestingly besides sulfate and glucuronide conjugates some flavonoid

glycoside conjugates have been found in human breast milk (Table 3). From the 9 ellagic

acid metabolites, urolithin A, isourolithin A and urolithin B and respective sulfate and

glucuronide metabolites were reported together with dimethyl ellagic acid-glucuronide, but

not ellagic acid (Table 4, Figure 4). Regarding the low molecular weight phenolics detected,

these ranged from benzoic acids, benzaldehydes, phenylacetic acids, 3-(phenyl)propanoic

acids, cinnamic acids, 5-(phenyl)-γ-valerolactones, hippuric acids and chlorogenic acid

(Table 5, Figure 4). Anthocyanins, isoflavones, flavanones and ellagic acid metabolites have

not been detected in all types of milk, by contrast with the remaining (poly)phenolic classes

that have been detected across all the different types of milk (colostrum, transitional and

mature). It is however important to note that most studies have used one type of milk only,

mature milk, thus explaining why several (poly)phenols have been detected in only one milk

type.

Among the flavan-3-ols, commonly found in chocolate(49), epigallocatechin-gallate was the

molecule detected at highest concentrations in breast milk, ranging from 0.67 to 1.12μM

(Figure 5A, Table 3). In previously reported intervention studies, reviewed in (50), this

molecule was detected in plasma, on average, at much lower concentrations, ranging from

0.03 to 0.38μM(50). Meanwhile, a more recent review shown higher plasma concentrations

with a mean Cmax across several studies of 0.87 ± 1.33μM, on par with breast milk

concentrations(51). By contrast, other flavan-3-ols like (epi)catechin, was detected at higher

concentration in plasma ranging from 0.09 to 1.10μM, in comparison to breast milk of 0.03 to

0.24μM(50). Meanwhile, quercetin was the flavonol detected in highest concentrations in

human breast milk ranging from 0.05 to 0.15μM (Figure 5B, Table 3). Remarkably in the

study performed by Zhang et al. 2018 measuring quercetin in both breast milk and plasma of

the mothers, it was shown that quercetin was more abundant in breast milk and urine in

comparison with plasma(44).

Regarding the flavanones naringenin and hesperidin, commonly found in citric fruits(49),

have been detected in plasma at concentrations ranging from 0.13 to 1.50μM and 0.21 to

0.87μM respectively (Figure 5C, Table 3). Meanwhile, in breast milk both flavanones have

been detected at lower concentrations ranging between 0.01 to 0.91µM for naringenin and

from 0.004 to 0.46µM for hesperidin (Table 3). Regarding isoflavones, daidzein and

genistein have been found in plasma ranging from 0.76 to 3.00µM and 1.26 to 4.50µM,

respectively(50). Meanwhile, in breast milk these two isoflavonoids have been found in much

lower concentrations ranging from 0.009 to 0.10µM and 0.005 to 0.12µM respectively

(Figure 5C, Table 3).

The urolithin metabolites urolithin A-glucuronide and urolithin B-glucuronide were the two

most abundant ellagic acid metabolites found in breast milk at 0.03µM and 0.02µM

respectively (Figure 5D, Table 4). In plasma these two metabolites have been found at

identical concentrations of 0.02µM, similar to those of breast milk(52). On the opposite

direction, urolithin A-sulfate detected in breast milk ranging from 0.008 to 0.02µM (Figure 5,

Table 4), was detected at much higher concentrations in plasma of 0.45µM(52).

Meanwhile, a recent literature review revealed the full list of low molecular weight phenolic

metabolites present in human blood(26). From this list of 137 phenolic metabolites detected

in human blood, only 58 have been detected and or quantified in human breast milk (Table

5). Most of these metabolites have been found in significantly higher concentrations in

human plasma in comparison with human breast milk. For example, regarding the phenolic

acid 3,4-dihydroxybenzoic acid and benzaldehyde 3,4-dihydroxybenzaldehyde, these have

been found in breast milk at concentrations ranging from 0.01 to 0.02µM and 0.009 to

0.01µM (Figure 5E, Table 5). While in plasma, these metabolites have been found up to

16µM and 0.03µM respectively. Meanwhile, 4-hydroxyphenyl acetic acid, 4-hydroxy-3-

methoxycinnamic acid (ferulic acid) and 3-methoxycinnamic acid-4-glucuronide (ferulic acid-

glucuronide) have been found in breast milk up to 0.27µM, 0.13µM and 0.3µM respectively

(Figure 5F and Table 5). Whereas in plasma these have been found at 2.6µM, 0.42µM and

0.36µM respectively. Noteworthy, the metabolite detected at higher concentrations in human

breast milk was 3,4,5-trihydroxybenzoic acid with a range of 0.06 to 0.66 µM (Figure 5E,

Table 5) detected to a lesser extent in plasma 0.12 ± 0.032µM, reviewed in (26).

Figure 5 – Range of concentrations of (poly)phenols detected in human breast milk. (A) flavan-3-ols,

(B) flavonols, (C) flavanones and isoflavones, (D) ellagic acid metabolites, (E) benzoic acids and

benzaldehydes, (F) phenylacetic, cinnamic acids, chlorogenic acids and phenyl-γ-valerolactones.

Each dot represents the different concentrations reported in Tables 3, 4 and 5. Val – valeric acid; gluc

– glucuronide.

Interestingly several classes of low molecular weight phenolics have not been detected in

human breast milk. This may be related with the lack of standards and/or a target analysis

excluding quantification of several metabolites, or the complete absence of this metabolites

in human breast milk. Examples of such metabolites not detected in human breast milk are :

2-(phenyl)propanoic acid, mandelic acid, cinnamoylglycine, 4-hydroxy-5-(phenyl)valeric acid,

5-(phenyl)valeric acid, (phenyl)ethanol or 4-ethylbenzenes. Regarding ellagic acid

metabolites, besides the 9 ellagic acid metabolites found in human breast milk and found in

blood, others have been found in human blood but not in human breast milk, namely urolithin

C, urolithin C glucuronide and urolithin C sulfate (34).

Overall, several reasons might explain the discrepancy between the number of (poly)phenols

detected in blood versus human breast milk. Noteworthy the data obtained for plasma and

breast milk samples have been obtained from different populations with probably differences

in the dietary exposure of (poly)phenols and in the absorption and metabolism of these

compounds. A particular relevant question is the possible changes on the metabolism of

(poly)phenols of recent post-partum volunteer.   Large studies quantifying (poly)phenols in

both plasma and breast milk of the same volunteer are required comparing concentrations in

both fluids and addressing this possibility. In the paper of Zhang *et al.*, most of the identified

metabolites were detected in the three biological samples (plasma and urine of two

volunteers and breast milk of another volunteer) and some were present in urine and breast

milk but not in plasma. This may reflect some intrinsic physical chemical property of each

compound to either stay in plasma or being rapidly eliminated from blood and accumulate in

urine and breast milk. Other factors could be i) their absence from human breast milk due to

the lack of specific transporters impairing their path through the mammary tissue, ii) the

timepoints used for the sampling and further quantification of the (poly)phenols metabolites

in the milk iii) lower concentrations in human breast milk (below limit of quantification) in

comparison with the already reported in circulation, iv) the fact these (poly)phenols

metabolites have never been searched in human breast milk due to the lack of available

standards, v) the extraction method is not fully compatible to all (poly)phenol metabolites.

One unsolved question that its understanding can shed light to some of these questions is

the mechanism of transport allowing (poly)phenols and/or metabolites to reach human

breast milk. The transport and delivery of (poly)phenols to the mammary glands is still

unknown and may result from passive diffusion, active transport, or carrier mediated

transport. For flavonoids, several methods of transport have been proposed to cross several

tissues like the gut from passive diffusion to mediated transport, especially by ATP-binding

cassette transporter (ABC transporters) and organic acid transporters (OAT), reviewed in

(53). For phenolic metabolites it is hypothesized that passive transport might be the main

route of transport across the tissue, although some transporters have already been

described. These include gallic acid through OAT3 (54) and homovanillic acid through

rOAT3 (55). Interestingly homovanillic acid is both an endogenous molecule, a metabolite of

dopamine and a phenolic metabolite result of microbiota catabolism of flavonoids. Other

phenolic metabolites that also result from endogenous pathways like hippuric acid and 2-

(3,4-dihydroxyphenyl)acetic acid (DOPAC) that might benefit from the endogenous routes of

transport. Furthermore, it also offers the possibility that structurally similar phenolics might

share the same routes.

4 The potential health benefits of (poly)phenols and phenolic metabolites in human breast milk

Although multiple studies have reported the protective effects of (poly)phenols against inflammation, oxidative stress and cardiometabolic stress, and the potential of isoflavones as phytoestrogens, the full spectrum of effects of (poly)phenols in human breast milk, both from the mother and the newborn perspective, has not been fully explored. Across the different studies reported in the literature the evaluation of the impact of (poly)phenols detected in human breast milk have been rather limited to the anti-oxidative properties of milk or the quantification of phytoestrogens and its impact on the newborn development.

Regarding the anti-oxidative properties of (poly)phenols in human breast milk Poniedzialek *et al.*, showed that an increase in total (poly)phenols in human breast milk associated with a higher total antioxidant capacity that were positively correlated with vegetable consumption (56). Total (poly)phenols also correlated negatively with malondialdehyde content. Noteworthy it is important to bring attention to the high degree of variability of samples collected. Li et al., compared the total (poly)phenol content in samples from breast milk and infant formula. In this case no significant change was detected as the variability within breast milk and infant formulas was significant (422 – 751 mg/kg and 329 – 797 mg/kg of ferulic acid equivalents respectively) (57).

A different study by Silberstein *et al.*, showed that the (poly)phenolic content in breast milk seems to be influenced by maternal health status (58). The study has shown that the breast milk composition of preeclampsia women presents a 33% increase in total (poly)phenol content in comparison with healthy women (58). The increase in total (poly)phenols in mothers with preeclampsia was associated with a reduction in about 20% the levels of lipid oxidation in colostrum in comparison with healthy women (58). Unfortunately, the authors only measured the total amount of (poly)phenols and did not investigate the presence or effects of specific (poly)phenols or their metabolites.

Concerning isoflavones, these have been classified as phytoestrogen for their chemical

similarity with estradiol and the capability to induce estrogenic or anti-estrogenic effects

depending on the dose (59). Isoflavones as phytoestrogens bind to estrogen receptors alpha

and beta (59). Isoflavones are present across several fruits and legumes with significant

relevance in soybeans and soy-based produces like soy milk and tofu. For their capability to

act as phytoestrogens, soy and soy-based products have been used in infant formulas in the

last century and their effects analyzed.

Setchell et al., compared the presence of isoflavones in 4-month-old infant blood samples

consuming human breast milk, soy-based infant formulas, and cow-based milk formulas

(60). The concentration of isoflavones circulating in babies fed with human breast milk was

on average 4.7 ug/L in comparison with the 9.4 ug/L of cow-based infant formula and the

979.7 ug/L of soy-based formula. This high plasma isoflavones concentrations in infants

consuming soy-based formula are however much higher than the normal estradiol

concentrations for infants of this age. One phenomenon detected was the lack of isoflavones

metabolites, namely equol and its metabolites, from soy-based infant formula since the

formation of this metabolites are largely dependent on the gut microbiota of the mother (60).

Meanwhile, Rosa et al. also showed a significant difference on the urinary phenolic

metabolites of 3-month-old infants feed with breast milk, cow-based infant formula, and soy-

based infant formula (61). In this study the overall quantity of phenolic metabolites excreted

in infant urine was 2-fold higher for some metabolites, namely 3′-hydroxyphenylacetic acid

and 4′-hydroxyphenylacetic acid in infants feed with soy-based infant formula in comparison

with human breast milk feed infants (61).

Although the evidence suggests an increase of isoflavones levels in infants fed with soy-

based formulas there is no clear evidence of a health benefit. In fact, a meta-analysis could

not find any negative effects of a high isoflavone intake from soy formulas, but also no

benefits, on endocrine and other physiological functions of breastfeeding (62). The authors

speculated that most isoflavones detectable in the plasma of soy fed infants are conjugated to sugars, which cannot link to isoflavone receptors.

Regarding the cognitive developmental status of infants, Andres *et al.*, 2012 evaluated 1 year old infants consuming breast milk, cow-based milk formula or soy-based milk formula. In this study infants were assessed using Bayley Scales of Infant Development (BSID), from which the Mental Developmental Index (MDI) and Psychomotor Development Index (PDI) were derived (63). Small but statistically significant effects of the diet on the MDI scores were seen for infants 6 months or older. Breastfed infants had significantly higher scores than soy fed infants at ages 6, 9, and 12 months and significantly higher scores than cow-based milk fed infants at ages 9 and 12 months. Although these effects reached statistical significance, the MDI scores were within the expected normal range, and the differences were very small. Significant effects of the diet on the PDI scores were transient. Soy fed infants had significantly lower PDI scores, although small, compared with breastfed infants, and seen only at 6 months. Furthermore, infants were also assessed with the Preschool Language Scale-3 (PLS-3) by using the expressive communication and auditory comprehension subscales. In PLS-3, only cow-based milk fed infants had significantly lower scores compared with breastfed infants at ages 3 and 6 months, but again all groups were inside the normal range (63).

Ostrom *et al.*, also observed the immune status of infants fed with soy-based formulas and human milk/infant formula feed infants (64,65). In this study infants were immunized against *Haemophilus influenzae* type b polysaccharide, diphtheria toxoid, tetanus toxoid, and oral poliovirus of children and their responses evaluated at 6, 7 and 12 months of age. Antibodies against *H. influenzae* type b at 7 and 12 months were higher significantly higher in infants fed with soy-based milk (65). In contrast, human milk/infant formula fed infants had higher poliovirus neutralizing antibodies at 12 months of age. Serum IgG and IgA levels were similar between groups as well as morbidly through the first year of life. Only physician-reported diarrhea was different between groups fed with human milk/infant formula having

529 less cases than the soy group (65). Latter Cordle et al., with the same cohort showed that

530 the number and percentage of B, T and NK lymphocytes were within age-related normal

531 ranges with minor differences between soy formula and human milk/infant formula fed

532 infants (64) . Overall, no differences were detected between the two groups due to soy-

533 based formulas consumption suggesting normal immune system development.

5. Conclusions and future perspectives

In this literature search we have listed the (poly)phenols and their metabolites, namely

flavonoids, ellagic acids and phenolics detected in human breast milk. Nonetheless, the

information available in the literature about the presence of (poly)phenols and/or their

metabolites reported in human breast milk is still in its infancy and requires further studies.

Many (poly)phenols and their metabolites have been detected in human circulation (26), yet

their presence in human milk have not been fully explored, due to several factors mentioned

before. Meanwhile, several nuances in the design of the studies performed may be hindering

the identification and their quantification in breast milk such as the timepoint of collection,

volume, extraction and method of quantification that may still require further optimizations.

Concentrations of some (poly)phenol and their metabolites in human breast milk may be

dependent on the diet of the mother, demonstrated by some intervention studies using

(poly)phenols rich foods or the stratification of volunteers. This type of pattern has also been

observed, with an increase in sugar and fat in human breast milk after mother ingested

sugar and fat enriched diets (66). The type of milk (colostrum, transitional or mature) did not

seem to make an impact in the quantification of some (poly)phenols. Several factors may still

require further investigation such as mother's interindividual differences (genetic, metabolic,

microbiota) or even variations caused by the circadian rhythm on breast milk composition

(66). In fact, most studies have not reported the time of collection and volume of breast milk,

which may be a big limitation, as milk production and composition may vary according to the

mothers and child dietary needs across the day. Some of the mentioned studies have managed this issue by assuring the collection of the full content of breast milk, choosing a specific time of the day for collection of all volunteers. Notwithstanding, information on how (poly)phenol composition varies on breast milk during the day is still nonexistent. Additionally, most studies have used small sample sizes that may overlook interindividual differences. Further studies addressing these issues may give a better insight on the presence of (poly)phenols and/or their metabolites in human breast milk and the impact of diets like the Mediterranean diet, vegetarian diet or vegan diets on the compounds present in human milk.

The studies on the potential health benefits to the infant of mother's (poly)phenols consumption and their presence in breast milk have been limited. The anti-oxidative properties of breast milk as function of total (poly)phenols have been performed, yet these should be looked has rather rough indicators. Measurement of general markers of antioxidant status, such as ORAC, TRAP, FRAP and TEAC are inappropriate methods for clinical studies because of the broad range of compounds (e.g., uric acid, albumin) that may interfere with the results of these analyses (67,68). More suitable markers for the increased cellular antioxidant potential may include nuclear Nrf-2 DNA binding capacity and NQO1 protein levels, which were observed to increase following (poly)phenol intake and not following a challenge meal alone (69).

The presence of phytoestrogens like isoflavones in human breast milk has been studied due to their potential to mimic estrogens. Several studies have focused on the comparison between human breast milk and soy-based infant formulas rich in isoflavones. Nonetheless, no clear conclusion has been reached about the potential health benefit of soy-based milk. Although (poly)phenols have been known for their anti-inflammatory properties, until now only one study has focused on the immunity of the infant and the presence of (poly)phenols in the breast milk (64). Newborns and especially pre-term infants can suffer from severe inflammatory conditions yet our knowledge of (poly)phenols impact in these conditions is

lacking as this study has never been addressed.Overall, there are clear gaps in our current

knowledge concerning what metabolites from dietary (poly)phenols appear in human breast

milk and their quantification. Moreover, this hampers our understanding of their potential

health benefits for the infant. At the present date the scientific data on the health potential of

(poly)phenols in adults is vast, yet very little is known about their effect in infants that

received them through milk. It will be important to design studies that make it possible to

relate the milk composition in (poly)phenol metabolites with infant's health outcomes. Our

understanding of the potential health benefits of mother's diets rich in (poly)phenols for the

newborn have a huge potential to help clinicians to deal with such a fragile phase of life of

infants with health complications. This will open a new way for the mothers to provide the

conditions for a strong and healthy growth of their child.

594 6. Acknowledgments

The authors gratefully acknowledge the support given by Doctor Teresa Costa regarding the

literature search process. This work has received funding from the European Research

Council (ERC) under the European Union's Horizon 2020 research and innovation program

under grant agreement No 804229. INOVA4Health Research Unit (LISBOA-01-0145-

FEDER-007344). Authors would also like to acknowledge FCT for financial support of D.C.

(2020.04630.BD).

602 7. Author contributions

Diogo Carregosa: Conceptualization; Data curation; Formal analysis; Investigation;

Methodology; Resources; Software; Visualization; Writing – original draft. **Inês P. Silva**:

Data curation; Formal analysis; Investigation; Methodology; Resources; Software;

Visualization; Writing – original draft. **Carolina Teixeira**: Data curation; Formal analysis;

Investigation; Methodology; Resources; Software; Visualization; Writing – original draft.

Mariana Baltazar: Data curation; Formal analysis; Investigation; Methodology; Resources;

Software; Visualization; Writing – original draft. **Rocio García-Villalba**: Formal analysis;

Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Filipa Soares Vieira: Validation; Visualization; Writing – review & editing. **Mónica Marçal**:

Validation; Visualization; Writing – review & editing. **Madalena Tuna**: Formal analysis;

Supervision; Validation; Visualization; Writing – original draft; Writing – review &

editing. **Cláudia Nunes dos Santos**: Conceptualization; Data curation; Formal analysis;

Project administration; Supervision; Writing – review & editing

617 8. References

1.   Cortez MV, Soria EA. The Effect of Freeze-Drying on the Nutrient, Polyphenol, and

Oxidant Levels of Breast Milk. Breastfeeding Medicine. Mary Ann Liebert Inc.; 2016. p.

551–4.

2.   Lu Z, Chan Y-T, Lo KK-H, Wong VW-S, Ng Y-F, Li S-Y, Ho W-W, Wong M-S, Zhao D.

Levels of polyphenols and phenolic metabolites in breast milk and their association

with plant-based food intake in Hong Kong lactating women. Food Funct

2021;12:12683–95.

3.   Collado MC, Delgado S, Maldonado A, Rodríguez JM. Assessment of the bacterial

diversity of breast milk of healthy women by quantitative real-time PCR. Lett Appl

Microbiol 2009;48:523–8.

4.   Valls-Bellés V, Abad C, Hernández-Aguilar MT, Nacher A, Guerrero C, Baliño P, Romero

FJ, Muriach M. Human Milk Antioxidative Modifications in Mastitis: Further Beneficial

Effects of Cranberry Supplementation. Antioxidants 2021;11:51.

5.   Geneva: World Health Organization. Guideline: Counselling of women to improve

breastfeeding practices . Licence: CC BY-NC-SA 30 IGO 2018;

6.   Lorenzetti S, Plösch T, Teller IC. Antioxidative Molecules in Human Milk and

Environmental Contaminants. Antioxidants 2021;10:550.

7.   Pillay J, Davis TJ. Physiology, Lactation. 2022.

8.   Ríos J, Valero-Jara V, Thomas-Valdés S. Phytochemicals in breast milk and their

benefits for infants. Critical Reviews in Food Science and Nutrition. Bellwether

Publishing, Ltd.; 2021.

9.   Sánchez-Hernández S, Esteban-Muñoz A, Samaniego-Sánchez C, Giménez-Martínez R,

Miralles B, Olalla-Herrera M. Study of the phenolic compound profile and antioxidant

activity of human milk from Spanish women at different stages of lactation: A

comparison with infant formulas. Food Research International 2021;141:110149.

10.   Ríos J, Valero-Jara V, Thomas-Valdés S. Phytochemicals in breast milk and their

benefits for infants. Crit Rev Food Sci Nutr 2022;62:6821–36.

11.   Tsopmo A. Phytochemicals in Human Milk and Their Potential Antioxidative

Protection. Antioxidants 2018;7:32.

12.   Slavin JL. Phytoestrogens in breast milk--another advantage of breast-feeding? Clin

Chem 1996;42:841–2.

13.   del Rio D, Rodriguez-Mateos A, Spencer JPE, Tognolini M, Borges G, Crozier A. Dietary

(Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of

Protective Effects Against Chronic Diseases. Antioxid Redox Signal [Internet] Mary Ann

Liebert Inc; 2013;18:1818–92. Available from:

http://www.liebertpub.com/doi/10.1089/ars.2012.4581

14.   Song BJ, Jouni ZE, Ferruzzi MG. Assessment of phytochemical content in human milk

655   during different stages of lactation. Nutrition 2013;29:195–202.

656   15.   Hussain T, Tan B, Yin Y, Blachier F, Tossou MCB, Rahu N. Oxidative Stress and

657   Inflammation: What Polyphenols Can Do for Us? Oxid Med Cell Longev 2016;2016:1–

658   9.

659   16.   Carregosa D, Mota S, Ferreira S, Alves-Dias B, Loncarevic-Vasiljkovic N, Crespo CL,

660   Menezes R, Teodoro R, Santos CN dos. Overview of Beneficial Effects of (Poly)phenol

661   Metabolites in the Context of Neurodegenerative Diseases on Model Organisms.

662   Nutrients 2021;13:2940.

663   17.   Raimundo AF, Félix F, Andrade R, García-Conesa M-T, González-Sarrías A, Gilsa-Lopes

664   J, do Ó D, Raimundo A, Ribeiro R, Rodriguez-Mateos A, et al. Combined effect of

665   interventions with pure or enriched mixtures of (poly)phenols and anti-diabetic

666   medication in type 2 diabetes management: a meta-analysis of randomized controlled

667   human trials. Eur J Nutr 2020;59:1329–43.

668   18.   Zhou Y, Zheng J, Li Y, Xu D-P, Li S, Chen Y-M, Li H-B. Natural Polyphenols for Prevention

669   and Treatment of Cancer. Nutrients 2016;8:515.

670   19.   Santos CN, Gomes A, Oudot C, Dias-Pedroso D, Rodriguez-Mateos A, Vieira HLA,

671   Brenner C. Pure Polyphenols Applications for Cardiac Health and Disease. Curr Pharm

672   Des 2018;24:2137–56.

673   20.   García-Villalba R, Giménez-Bastida JA, Cortés-Martín A, Ávila-Gálvez MÁ,

674   Tomás-Barberán FA, Selma MV, Espín JC, González-Sarrías A. Urolithins: a

675   Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut

676   Microbiota. Mol Nutr Food Res 2022;66:2101019.

677   21.   Carregosa D, Carecho RM, Figueira I, Santos CN. Low molecular weight metabolites
678   from polyphenols as effectors for attenuating neuroinflammation. J Agric Food Chem
679   [Internet] 2019;acs.jafc.9b02155. Available from:
680   http://pubs.acs.org/doi/10.1021/acs.jafc.9b02155

681   22.   Crespy V, Morand C, Besson C, Manach C, Demigne C, Remesy C. Quercetin, but not Its
682   Glycosides, Is Absorbed from the Rat Stomach. J Agric Food Chem 2002;50:618–21.

683   23.   Passamonti S, Vrhovsek U, Vanzo A, Mattivi F. The stomach as a site for anthocyanins
684   absorption from food [1]. FEBS Lett 2003;544:210–3.

685   24.   Talavéra S, Felgines C, Texier O, Besson C, Lamaison J-L, Rémésy C. Anthocyanins Are
686   Efficiently Absorbed from the Stomach in Anesthetized Rats. J Nutr 2003;133:4178–82.

687   25.   Piskula MK, Yamakoshi J, Iwai Y. Daidzein and genistein but not their glucosides are
688   absorbed from the rat stomach. FEBS Lett 1999;447:287–91.

689   26.   Carregosa D, Pinto C, Ávila-Gálvez MÁ, Bastos P, Berry D, Santos CN. A look beyond
690   dietary (poly)phenols: The low molecular weight phenolic metabolites and their
691   concentrations in human circulation. Compr Rev Food Sci Food Saf 2022;21:3931–62.

692   27.   Tomás-Barberán FA, García-Villalba R, González-Sarrías A, Selma M v., Espín JC. Ellagic
693   Acid Metabolism by Human Gut Microbiota: Consistent Observation of Three Urolithin
694   Phenotypes in Intervention Trials, Independent of Food Source, Age, and Health
695   Status. J Agric Food Chem 2014;62:6535–8.

696   28.   Mena P, Bresciani L, Brindani N, Ludwig IA, Pereira-Caro G, Angelino D, Llorach R,
697   Calani L, Brighenti F, Clifford MN, et al. Phenyl-γ-valerolactones and phenylvaleric
698   acids, the main colonic metabolites of flavan-3-ols: synthesis, analysis, bioavailability,
699   and bioactivity. Nat Prod Rep [Internet] Royal Society of Chemistry ({RSC}); 2019;
700   Available from: http://xlink.rsc.org/?DOI=C8NP00062J

701   29.   Heinonen S-M, Hoikkala A, Wähälä K, Adlercreutz H. Metabolism of the soy

702   isoflavones daidzein, genistein and glycitein in human subjects. J Steroid Biochem Mol

703   Biol [Internet] Elsevier {BV}; 2003;87:285–99. Available from:

704   https://linkinghub.elsevier.com/retrieve/pii/S096007600300414X

705   30.   Tomás-Barberán FA, González-Sarrías A, García-Villalba R, Núñez-Sánchez MA, Selma

706   M v., García-Conesa MT, Espín JC. Urolithins, the rescue of "old" metabolites to

707   understand a "new" concept: Metabotypes as a nexus among phenolic metabolism,

708   microbiota dysbiosis, and host health status. Mol Nutr Food Res 2017;61:1500901.

709   31.   Rothwell JA, Perez-Jimenez J, Neveu V, Medina-Remon A, M'Hiri N, Garcia-Lobato P, Manach

710   C, Knox C, Eisner R, Wishart DS, et al. Phenol-Explorer 3.0: a major update of the Phenol-

711   Explorer database to incorporate data on the effects of food processing on polyphenol

712   content. Database [Internet] Oxford University Press ({OUP}); 2013;2013. Available from:

713   https://academic.oup.com/database/article-lookup/doi/10.1093/database/bat070

714   32.   da Silva A, Giacomoni F, Pavot B, Fillâtre Y, Rothwell JA, Sualdea BB, Veyrat C, Garcia-Villalba

715   R, Gladine C, Kopec R, et al. PhytoHub V1. 4: A new release for the online database dedicated

716   to food phytochemicals and their human metabolites. Proceedings of the 1st International

717   Conference on Food Bioactivities & Health, Norwich, UK. 2016. p. 13–5.

718   33.   Sud M, Fahy E, Cotter D, Azam K, Vadivelu I, Burant C, Edison A, Fiehn O, Higashi R, Nair KS, et

719   al. Metabolomics Workbench: An international repository for metabolomics data and

720   metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic

721   Acids Res 2016;44:D463–70.

722   34.   Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, et

723   al. HMDB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res 2022;50:D622–

724   31.

35.   Zhou W, Wu H, Wang Q, Zhou X, Zhang Y, Wu W, Wang Y, Ren Z, Li H, Ling Y, et al.

Simultaneous determination of formononetin, biochanin A and their active metabolites in

human breast milk, saliva and urine using salting-out assisted liquid-liquid extraction and

ultra high performance liquid chromatography-electrospray ionization tandem mass

spectrum. Journal of Chromatography B 2020;1145:122108.

36.   Jochum F, Alteheld B, Meinardus P, Dahlinger N, Nomayo A, Stehle P. Mothers' Consumption

of Soy Drink But Not Black Tea Increases the Flavonoid Content of Term Breast Milk: A Pilot

Randomized, Controlled Intervention Study. Ann Nutr Metab 2017;70:147–53.

37.   Franke AA, Custer LJ. Daidzein and genistein concentrations in human milk after soy

consumption. Clin Chem 1996;42:955–64.

38.   Franke AA, Custer LJ, Tanaka Y. Isoflavones in human breast milk and other biological fluids.

Am J Clin Nutr 1998;68:1466S-1473S.

39.   Franke AA, Custer LJ, Wang W, Shi CY. HPLC Analysis of Isoflavonoids and Other Phenolic

Agents from Foods and from Human Fluids. Exp Biol Med 1998;217:263–73.

40.   Khymenets O, Rabassa M, Rodríguez-Palmero M, Rivero-Urgell M, Urpi-Sarda M, Tulipani S,

Brandi P, Campoy C, Santos-Buelga C, Andres-Lacueva C. Dietary Epicatechin Is Available to

Breastfed Infants through Human Breast Milk in the Form of Host and Microbial Metabolites.

J Agric Food Chem 2016;64:5354–60.

41.   Romaszko E, Marzec-Wróblewska U, Badura A, Buciński A. Does consumption of red

grapefruit juice alter naringenin concentrations in milk produced by breastfeeding mothers?

PLoS One 2017;12:e0185954.

42.   Romaszko E, Wiczkowski W, Romaszko J, Honke J, Piskula MK. Exposure of breastfed infants

to quercetin after consumption of a single meal rich in quercetin by their mothers. Mol Nutr

Food Res 2014;58:221–8.

43.   Henning SM, Yang J, Lee R-P, Huang J, Thames G, Korn M, Ben-Nissan D, Heber D, Li Z.

Pomegranate juice alters the microbiota in breast milk and infant stool: a pilot study. Food

Funct 2022;13:5680–9.

44.   Zhang X, Sandhu A, Edirisinghe I, Burton-Freeman B. An exploratory study of red raspberry (

Rubus idaeus L.) (poly)phenols/metabolites in human biological samples. Food Funct

2018;9:806–18.

45.   Feliciano RP, Boeres A, Massacessi L, Istas G, Ventura MR, Nunes dos Santos C, Heiss C,

Rodriguez-Mateos A. Identification and quantification of novel cranberry-derived plasma and

urinary (poly)phenols. Arch Biochem Biophys [Internet] Elsevier {BV}; 2016;599:31–41.

Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003986116300145

46.   Cortés-Martín A, García-Villalba R, García-Mantrana I, Rodríguez-Varela A, Romo-Vaquero M,

Collado MC, Tomás-Barberán FA, Espín JC, Selma MV. Urolithins in Human Breast Milk after

Walnut Intake and Kinetics of *Gordonibacter* Colonization in Newly Born: The Role of

Mothers' Urolithin Metabotypes. J Agric Food Chem 2020;68:12606–16.

47.   Henning SM, Wallenstein MB, Weigel N, Johnson C, Yang J, Lee R-P. Appearance of Ellagic

Acid Metabolites from Pomegranate Juice in Breast Milk: A Case Report. Ann Clin Case Rep

2019;4:1738.

48.   Nalewajko-Sieliwoniuk E, Hryniewicka M, Jankowska D, Kojło A, Kamianowska M, Szczepański

M. Dispersive liquid–liquid microextraction coupled to liquid chromatography tandem mass

spectrometry for the determination of phenolic compounds in human milk. Food Chem

2020;327:126996.

49.   Pinto P, Santos CN. Worldwide (poly)phenol intake: assessment methods and identified gaps.

Eur J Nutr 2017;56:1393–408.

50.   Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review

of 93 intervention studies. Am J Clin Nutr [Internet] Oxford University Press ({OUP});

2005;81:243S-255S. Available from:

https://academic.oup.com/ajcn/article/81/1/243S/4607529

51.   di Pede G, Mena P, Bresciani L, Achour M, Lamuela-Raventós RM, Estruch R, Landberg R,

Kulling SE, Wishart D, Rodriguez-Mateos A, et al. Revisiting the bioavailability of flavan-3-ols

in humans: A systematic review and comprehensive data analysis. Mol Aspects Med

2023;89:101146.

52.   Ludwig IA, Mena P, Calani L, Borges G, Pereira-Caro G, Bresciani L, del Rio D, Lean MEJ,

Crozier A. New insights into the bioavailability of red raspberry anthocyanins and

ellagitannins. Free Radic Biol Med 2015;89:758–69.

53.   Williamson G, Kay CD, Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary

Flavonoids: A Review from a Historical Perspective. Compr Rev Food Sci Food Saf

2018;17:1054–112.

54.   Wang L, Halquist MS, Sweet DH. Simultaneous determination of gallic acid and gentisic acid in

organic anion transporter expressing cells by liquid chromatography–tandem mass

spectrometry. Journal of Chromatography B 2013;937:91–6.

55.   Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang Y-S, Hosoya K, Terasaki T. Rat Organic Anion

Transporter 3 (rOAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the

Abluminal Membrane of Brain Capillary Endothelial Cells. Journal of Cerebral Blood Flow &

Metabolism 2003;23:432–40.

56.   Poniedziałek B, Rzymski P, Pięt M, Gąsecka M, Stroińska A, Niedzielski P, Mleczek M, Rzymski

P, Wilczak M. Relation between polyphenols, malondialdehyde, antioxidant capacity, lactate

dehydrogenase and toxic elements in human colostrum milk. Chemosphere 2018;191:548–

54.

57. Li W, Hosseinian FS, Tsopmo A, Friel JK, Beta T. Evaluation of antioxidant capacity and aroma

quality of breast milk. Nutrition 2009;25:105–14.

58. Silberstein T, Hamou B, Cervil S, Barak T, Burg A, Saphier O. Colostrum of Preeclamptic

Women Has a High Level of Polyphenols and Better Resistance to Oxidative Stress in

Comparison to That of Healthy Women. Oxid Med Cell Longev 2019;2019:1–5.

59. Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological

effect and bioavailability. Eur J Drug Metab Pharmacokinet 2013;38:15–25.

60. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and

the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 1998;68:1453S-1461S.

61. Rosa F, Mercer KE, Lin H, Sims CR, Pack LM, Goode G, Badger T, Andres A, Yeruva L. Early

Infant Formula Feeding Impacts Urinary Metabolite Profile at 3 Months of Age. Nutrients

2020;12:3552.

62. Vandenplas Y, Castrellon PG, Rivas R, Gutiérrez CJ, Garcia LD, Jimenez JE, Anzo A, Hegar B,

Alarcon P. Safety of soya-based infant formulas in children. British Journal of Nutrition

2014;111:1340–60.

63. Andres A, Cleves MA, Bellando JB, Pivik RT, Casey PH, Badger TM. Developmental Status of 1-

Year-Old Infants Fed Breast Milk, Cow's Milk Formula, or Soy Formula. Pediatrics

2012;129:1134–40.

64. Cordle CT;, Winship TR;, Schaller JP;, Thomas DJ*;, Buck RH;, Ostrom KM;, Jacobs JR;, Blatter

MM;, Cho S, Gooch WMI, et al. Immune Status of Infants Fed Soy-Based Formulas With or

Without Added Nucleotides for 1 Year: Part 2: Immune Cell Populations. J Pediatr

Gastroenterol Nutr 2002;34:145–53.

65.   Ostrom KM, Cordle CT, Schaller JP, Winship TR, Thomas DJ, Jacobs JR, Blatter MM, Cho S,

Gooch WM, Granoff DM, et al. Immune Status of Infants Fed Soy-Based Formulas With or

Without Added Nucleotides for 1 Year: Part 1: Vaccine Responses, and Morbidity. J Pediatr

Gastroenterol Nutr 2002;34:137–44.

66.   Ward E, Yang N, Muhlhausler BS, Leghi GE, Netting MJ, Elmes MJ, Langley-Evans SC. Acute

changes to breast milk composition following consumption of high-fat and high-sugar meals.

Matern Child Nutr 2021;17.

67.   Williamson G. Reporting of plasma antioxidant activities in human intervention studies in the

British Journal of Nutrition. British Journal of Nutrition 2019;122:721–2.

68.   Harnly J. Antioxidant methods. Journal of Food Composition and Analysis 2017;64:145–6.

69.   Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, Chaudhuri A,

Dandona P. A Resveratrol and Polyphenol Preparation Suppresses Oxidative and

Inflammatory Stress Response to a High-Fat, High-Carbohydrate Meal. J Clin Endocrinol

Metab 2011;96:1409–14.

70.   Min J, Wang Z, Liang C, Li W, Shao J, Zhu K, Zhou L, Cheng J, Luo S, Yu L, et al.

Detection of Phytoestrogen Metabolites in Breastfed Infants' Urine and the

Corresponding Breast Milk by Liquid Chromatography–Tandem Mass Spectrometry. J

Agric Food Chem 2020;68:3485–94.

Table 1 – Characteristics of studies detecting and quantifying (poly)phenols in human breast milk samples of mothers undergoing dietary interventions.

Diet/ Intervention	Duration of intervention	Sample type	N	Dietary recommendations and intake	Samples collected during intervention	Time of collection	Sample Treatment	Method of detection	(Poly)phenol detected	Reference
Dark chocolate	Single dose	M	2	No ingestion of other coca-based products	0, 2, 4, 6, 8, 10 and 12h	Whole BM content, upon pre-defined timepoint for collection.	Acidification with PO_4H_3 followed by SPE	UPLC-QQQ	Flavan-3-ols (epicatechin derivatives) Phenyl-γ-valerolactones	(40)
125g of red raspberry	1 week	M	1	-	0h and 2h on day 1 and day 7	-	SPE	UPLC-QTOF UPLC-QQQ	Anthocyanins Flavan-3-ols Flavonols Urolithins Phenyl- γ-valerolactones Phenolic acids	(44)
30g of peeled walnut	3 days	M	11	Avoid ellagitannin containing foods during the week before starting the intervention	0, 24, 48, and 72h	Entire BM content at the pre-defined timepoint: Morning collection.	ACN/formic acid (99:1) extraction	UPLC-QTOF	Urolithins	(46)
			27		72h					
500 mL soybean milk	Single dose	M	6	Isoflavones restriction	0.5, 3, 6, 9, 12 and 24h	Unknown amount of BM at the pre-defined timepoint for collection	Glucuronidase and sulfatase ACN	UPLC-Qtrap	Isoflavones (genistein/daidzein)	(35)
250 mL of red grapefruit juice	Single dose	M	14	No supplement usage Avoid fruits rich in naringenin	0, 1, 2, 3, 4, 5, 6, 12, 18, 24 and 36h	Entire BM content at the pre-defined timepoint for collection	Hexane Pepsin in HCl NaOH and glucuronidase and sulfatase Ethyl acetate extraction	HPLC-UV HPLC- Q	Flavanones (naringenin)	(41)

Food/Dose	Frequency	Sex	n	Diet restrictions	Collection timepoints	BM collection	Extraction/Enzyme	Analysis	Compounds	Ref
5, 10 or 20g of roasted soybeans	Day 0 day 1 and day 3 respectively	M	1	No alcohol Maintained regular diet	[a]	Unknown amount of BM at the pre-defined timepoint for collection	Glucuronidase and sulfatase Ethyl acetate extraction	HPLC-UV HPLC-ECD	Isoflavones (genistein/daidzein)	(39)
								HPLC-UV GC-MS	Isoflavones (genistein/daidzein)	(37)
5, 10, and 20 g roasted soybeans	day 1 and day 3 respectively	M, IF	1	No alcohol Maintained regular diet	[a]	Unknown amount of BM at the pre-defined timepoint for collection	Glucuronidase and sulfatase Ethyl acetate extraction	HPLC-UV	Isoflavones (genistein/daidzein)	(38)
250mL soy drink	Daily (in the morning) for 6 days	M	18	No consumption of flavonoid-rich beverages and foods	Day before intervention. Day 3, 6 of intervention. Day after intervention	5 min after breastfeeding starts (collected in the evening at 10h a.m)	Glucuronidase and sulfatase SPE	HPLC-ECD	Isoflavones (genistein/daidzein)	(36)
300mL black tea		M	18							
300mL water		M	8							
Onion soup	Single dose	M	11	5-day low quercetin diet	0, 3, 6, 12, 18, 24, 36, and 48 h	Unknown amount of BM at the pre-defined timepoint of collection	Hexane Glucuronidase and sulfatase Ethyl acetate extraction	HPLC-PDA-MS	Flavonols (Quercetin/ isorhamnetin)	(42)
227g of pomegranate juice	Daily for 2 weeks	M	2	2 weeks washout period of low (poly)phenol diet	Collection at day 0 and day 14 at 6 and 24 h post intake.	10mL of BM at the pre-defined timepoint of collection	ACN SPE	LC-MS/MS	Urolithins (Uro A glucuronide/ Dimethyl ellagic acid glucuronide)	(47)
227g of pomegranate juice	Daily for 2 weeks	M	12	2 weeks washout period of low (poly)phenol diet	Collection at day 0 and day 14 at 6 and 24 h after intake.	Unknown amount of BM at the pre-defined timepoint of collection	ACN SPE	LC-MS/MS	Urolithins (Uro A glucuronide/ Dimethyl ellagic acid glucuronide)	(43)

841   BM- Breast Milk, C- Colostrum, T- Transitional Milk, M- Mature Milk, IF- infant formula, ACN-acetonitrile, SPE- solid phase extraction, LC- Liquid
842   chromatography, HPLC- High performance liquid chromatography, UPLC/UHPLC- Ultra performance liquid chromatography, PDA- photodiode array
843   detector, ECD- electrochemical detector, UV- ultraviolet, GC- Gas chromatography, PO_4H_3 – phosphoric acid
844   [a] The three articles mentioned share the same experimental design. Exact sampling timepoints are not mentioned in text yet are shown in graph.
845   Notwithstanding, exact timepoint of collection could not be extracted from the graphs.
846

857 Table 2- Characteristics of studies detecting and quantifying (poly)phenols in human breast milk samples of free-living mothers.

Criteria for participation	Dietary recall or FFQ	Sample type	No volunteers	Samples collected during intervention	Time of collection	Sample Treatment	Method of detection	(poly)phenol detected	Reference
Adherence to Mediterranean Diet. (based on FFQ)	FFQ	C, T, M, IF	C: 7 [a] T: 7 [a] M: 7 [a] IF: 7	C: up to 5th day T:6th - 15th day M> 15th day	Beginning of each feeding	NaOH hydrolysis Hexane lipid precipitation Ethyl acetate extraction	UPLC-MS/MS	Phenolic acids Flavan-3-ols Flavonols	(9)
-	FFQ and 24h recall questionnaire in the day of sampling	C, T, M	C: 3 T: 11 M: 10	C: 1st - 5th T:6th - 15th M> 15th day	30-50mL of BM in the morning or through the day	Acidification with PO_4H_3 SPE	UPLC-MS/MS	Flavan-3-ols Phenolic acids	(40)
-	-	C, T, M, IF (non-differentiated)	6	-	Pool of different timepoints	NaOH hydrolysis Hexane lipid precipitation Ethyl acetate extraction	HPLC-UV	Phenolic acids	(57)
-	Volunteers divided in three groups according to FFQ: Low, medium, and higher (poly)phenol intake	M	30 volunteers for high and medium intake and 29 for low intake	Between 2 and 24 months	Entire BM content. All participant sample at the same time of the day	Hexane Acidified and treated with glucuronidase Ethyl acetate extraction	UHPLC-MS/MS	Flavan-3-ols Flavonols Flavanones Isoflavones	(2)
Free living	-	T, M	T: 17 M: 17	1, 4 13 weeks after infant birth	Morning between 10h and 13h	Hexane Pepsin in HCl NaOH and glucuronidase and sulfatase Ethyl acetate extraction	HPLC-MS/MS	Flavan-3-ols Flavanones Flavonols	(14)
Free living	-	C	13	-	-	Hexane $(NH_4)_2SO_4$ and ascorbic acid Glucuronidase and sulfatase	LC-ESI-MS/MS	Flavanones Isoflavones Phenolic	(48)

					treatment Ethyl acetate and acetonitrile extraction		acids	
Free living	FFQ and 24h dietary recall	-	50	-	>30 mL of BM in the morning after fasting	Ethyl acetate extraction Glucuronidase and sulfatase treatment Ethyl acetate extraction	LC-MS/MS	Isoflavones (70)

858 BM- Breast Milk, C- Colostrum, T- Transitional Milk, M- Mature Milk, IF- infant formula, ACN-acetonitrile, SPE- solid phase extraction, LC- Liquid
859 chromatography, HPLC- High performance liquid chromatography, UPLC/UHPLC- Ultra performance liquid chromatography, PO$_4$H$_3$ – phosphoric acid.
860 [a] Eighteen volunteers were included in each group, yet (poly)phenol quantifications were only performed to 7 of the 18 volunteers per group.
861

Flavonoids	Milk Type	Concentration (range) in nmol/L [a]	Reference
Anthocyanins			
Cyanidin-3-sophoroside	M	R.Q.	(44)
Cyanidin-3-2G-glucosylrutinoside	M	R.Q.	(44)
Cyanidin-3-glucoside	M	R.Q.	(44)
Pelargonidin-3-sophoroside	M	R.Q.	(44)
Cyanidin-3-rutinoside	M	R.Q.	(44)
Cyanidin-3-glucuronide	M	R.Q.	(44)
Methylcyanidin-3-sophoroside	M	R.Q.	(44)
Peonidin-3-glucoside	M	R.Q.	(44)
Flavonols			
Quercetin	M	150 [c]	(2) [f]
	T M	48.1 (40.0-77.6) 59.8 (33.1-108.6) [e]	(14) [f]
	M	68 [b]	(42) [f]
	C	105.22 (100.59 – 109.52) [d]	(48) [f]
Isoquercetin	C T M	0.11 (0.06-0.15) 0.19 (0.08-0.21) 0.16 (0.06-0.25)	(9)
Kaempferol	M	30 [c]	(2) [f]
	T M	15.7 (7.8-34) 34.8 (17.7-71.4) [e]	(14) [f]
Kaempferol-3-glucoside	C T M	2.36 (0-7.08) 3.02 (0.01-5.24) -	(9)
Flavan-3-ols			
Catechin	C T M	0.04 (0.02-0.05) 0.02 (0.01-0.03) 0.29 (0.08-0.42)	(9)
Catechin-glucuronide	M	R.Q.	(44)
	M	5.4 [c]	(2) [f]
Epicatechin	M	33 [c]	(2) [f]
	T M	90.5 (68.3-120.5) 249.2(63.7-828.5) [e]	(14)
Epicatechin-4-glucuronide	C, T	38 [b]	(40)
Epicatechin-2-sulfate	T, M	26 [b]	(40)
Methylepicatechin-3-sulfate	C, T, M	26 [b]	(40)
Epicatechin-gallate	T M	189.5 (55.7-609) 236.6 (62.2-646) [e]	(14) [f]
Epigallocatechin-gallate	T M	1119 (426-2365) 667 (215-1684) [e]	(14) [f]
Isoflavones			
Daidzein	M	68 [c]	(2) [f]
	M	104 [b]	(35) [f]
	M	60 [b, d]	(38) [f]
	M	9.3 [b]	(36)
	M	55 [b, d]	(37) [f]
	C	14.20 (0.83-79.46) [d]	(48) [f]
		37 (20-54)	(70) [f]

Genistein	M	99 [b]	(35)[f]
	M	65 [b, d]	(38)[f]
	M	4.5 [b]	(36)
	M	70 [b, d]	(37)[f]
	C	13.43 (0.93- 44.77) [d]	(48)[f]
	-	117 (105-130)	(70)[f]
Flavanone			
Naringenin	M	474 [c]	(2) [f]
	T M	252 (83-543) 210 (98-722) [e]	(14)[f]
	M	908 [b]	(41)[f]
	C	6.69 (1.41-22.30) [d]	(48)[f]
Hesperitin	T M	459 (107-1272) 393 (80-1603) [e]	(14)[f]
	C	4.11 (0.79-16.21) [d]	(48)[f]
Flavonoid metabolite			
Equol	M	102 [c]	(2)[f]
	-	8.000 (0.001-0.028)	(70)[f]

C- Colostrum, T- transitional milk, M- Mature Milk, R.Q.- Relative quantification

[a] The concentrations listed are the highest concentrations reported in each study or a range when
more than one concentration is presented . Studies reporting only relative quantification are
referred as R.Q (relative quantification).
[b] Studies reporting a Cmax values from a kinetic study.
[c] Highest reported concentration between the three experimental groups in the study (low, medium
and high (poly)phenol consumers).
[d] Approximate values extrapolated from the graph.
[e] Highest reported concentration between week 4 and 13 postpartum.
[f] This study reported the use of deconjugation enzymes that may impact the absolute value
reported.

Table 4 – Ellagic acid metabolites detected and quantified in human breast milk, and their

concentrations.

Ellagic acid metabolites	Milk Type	Quantification Cmax (range) in nmol/L	Reference	
Dimethyl Ellagic Acid-glucuronide	M	1.12 [c]	(47)	881
Urolithin A	M	4.7 (4-5) [a] 3.3 (1.4-7.8) [b]	(46)	882 883
Urolithin A-glucuronide	M	27.6 (9-78) [a] 31 (10-90) [b]	(46)	884 885
	M	36.28 [c]	(43)	886
Urolithin A-sulfate	M	7.9 (7-9) [a] 17.2 (7-40) [b]	(46)	887
Isourolithin A	M	2.7 (2-5) [b]	(46)	888
Isourolithin A-glucuronide	M	14.8 (6-23) [b]	(46)	889
Urolithin B	M	4.3 [b]	(46)	890
Urolithin B-glucuronide	M	19.8 (5-52) [b]	(46)	891
Urolithin B-sulfate	M	D.Q	(46)	892

893
894   M- Mature Milk, D.Q- Detected not quantified
895   [a] Detected in Metabotype A
896   [b] Detected in Metabotype B
897   [c] Maximal reported Cmax between the two participants and day 1, 7 and 14 after beginning of the
898   intervention.
899

900   Table 5- Low molecular weight phenolics detected in human breast milk, and their concentrations.

Phenolic Metabolite	Milk Type	Concentration (range) in nmol/L [a]	Reference
Benzenes			
1,2,3-trihydroxybenzene (pyrogallol)	C T M	0.75 (0.34-1.73) 0.95 (0.28-2.13) 1.66 (1.41-3.91)	(9)
Benzoic acids			
3,4,5-trihydroxybenzoic acid (gallic acid)	C T M	582 (375–721) 661 (434–816) 575 (434–816)	(9)
	M	61 [c]	(2)[f]
	M	R.Q.	(44)
	C	186.92 (178.70-194.57) [d]	(48)[f]
2,3-dihydroxybenzoic acid	M	R.Q.	(44)
2,5-dihydroxybenzoic acid	C T M	5.61 (4-8) 7.41 (3-15) 6.43 (0.29-11)	(9) [f]
2,6-dihydroxybenzoic acid		R.Q.	(44)
4-hydroxy-3-methoxybenzoic acid (vanillic acid)	C T M	5.96 (6-7) 7.05 (6-8) 6.56 (4-10)	(9) [f]
	M	R.Q.	(44)
3-methoxybenzoic acid-4-sulfate (vanillic acid-sulfate)	M	R.Q.	(44)
3-methoxybenzoic acid-4-glucuronide (vanillic acid-glucuronide)	M	R.Q.	(44)
4-methoxy-3-hydroxybenzoic acid (Isovanillic acid)	M	R.Q.	(44)
4-methoxy-benzoic acid-3-sulfate (Isovanillic acid-sulfate)	M	R.Q.	(44)
3,4-dihydroxybenzoic acid (protocatechuic acid)	C T M	15.16 (5-31) 22.55 (9-27) 13.16 (3-20)	(9)[f]
	M	770 [c]	(2)[f]
	M	R.Q.	(44)
3,4-dihydroxybenzoic acid-sulfate [b] (protocatechuic acid-sulfate)	M	R.Q.	(44)
2,4,6-trihydroxybenzoic acid	C T M	2.71 (1-6) 2.68 (1-4) 3.08 (0.25-6)	(9)
4-hydroxybenzoic acid	C T M	0.54 (0.24-0.90) 0.67 (0.44-0.94) 0.72 (0.26-1.9)	(9)
	M	R.Q.	(44)
	C, T, M	(4445-4598) [d]	(57)
benzoic acid-4-glucuronide	M	R.Q.	(44)
benzoic acid-4-sulfate	M	R.Q.	(44)
3-hydroxybenzoic acid	C T M	7.66 (3-14) 9.94 (6-12) 6.85 (3-8)	(9)
benzoic acid-3-glucuronide	M	R.Q.	(44)
methyl 4-hydroxybenzoate	M	R.Q.	(44)
methyl 3,4-dihydroxybenzoate	M	R.Q.	(44)

Benzaldehydes

3,4-dihydroxybenzaldehyde (protocatechualdehyde)	C T M	9.63 (3-17) 12.56 (7-16) 7.46 (3-10)	(9)
	M	R.Q.	(44)
4-hydroxybenzaldehyde (p-hydroxybenzaldehyde)	M	R.Q.	(44)
	C T M	1.09 (1-6) 3.54 (1-5) 1.62 (0.41-3)	(9)
benzaldehyde-4-glucuronide (4-hydroxybenzaldehyde-glucuronide)	M	R.Q.	(44)
4-hydroxy-3-methoxybenzaldehyde (vanillin)	C T M	5.84 (3-9) 7.83 (7-10) 5.56 (2-10)	(9)
2-hydroxy-3-methoxybenzaldehyde (o-vanillin)	C T M	1.61 (1.41-1.62) 6.06 (6-7) 12.22 (0.30-32)	(9)
2,4,6-trihydroxybenzaldehyde (phloroglucinaldehyde)	M	R.Q.	(44)

Cinnamic Acids

cinnamic acid (coumaric acid)	M	R.Q.	(44)
4'-hydroxy-3'-methoxycinnamic acid (ferulic acid)	C T M	0.62 (0.06-1.23) 0.71 (0.12-1.53) 0.34 (0.14-0.57)	(9)
	M	129 [c]	(2)[f]
	M	R.Q.	(44)
	C, T, M	(7339-7673) [d]	(57)
3'-methoxycinnamic acid-4'-glucuronide (ferulic acid-glucuronide)	M	R.Q.	(44)
3',4'-dihydroxycinnamic acid (caffeic acid)	C T M	14.15 (4-17) 17.28 (4-30) 12.32 (1-24)	(9)
	M	188 [c]	(2)[f]
	C	301.95 (129.32- 654.97) [d]	(48)[f]
3',4'-dihydroxycinnamic acid-sulfate [b] (caffeic acid-sulfate)	M	R.Q.	(44)
4'-methoxycinnamic acid	C T M	0.24 (0.02-0.67) 0.30 (0.14-0.48) 0.91 (0.06-2.42)	(9)
3',4'-dimethoxycinnamic acid (dimethylcinnamic acid)	C T M	0.14 (0.13-0.28) 0.56 (0.15-0.25) 0.18 (0.13-0.24)	(9)
4'-hydroxycinnamic acid (p-coumaric acid)	C T M	0.44 (0.24-0.59) 1.20 (0.27-2.31) 0.29 (0.15-0.49)	(9)
	C, T, M	(8474-8797) [d]	(57)
cinnamic acid-4'-sulfate (p-coumaric acid-sulfate)	M	R.Q.	(44)

3-(phenyl)propanoic acids

3-(3′-methoxyphenyl)propanoic acid-4′-glucuronide (dihydroferulic acid-glucuronide)	M	R.Q.	(44)
3′-methoxycinnamic acid-4′-sulfate (dihydroferulic acid-sulfate)	M	R.Q.	(44)
3-(3′,4′-dihydroxyphenyl)propanoic acid-sulfate [b] (dihydrocaffeic acid-sulfate)	M	R.Q.	(44)
3-(3′-hydroxyphenyl)propanoic acid	M	R.Q.	(44)
3-(phenyl)propanoic acid-3′-sulfate (3-(3-hydroxyphenyl)propanoic acid-sulfate)	M	R.Q.	(44)
Phenylacetic acids			
2′-hydroxyphenylacetic acid	M	R.Q.	(44)
3′-hydroxyphenylacetic acid	M	R.Q.	(44)
4′-hydroxyphenylacetic acid	M	R.Q.	(44)
4′-hydroxyphenylacetic acid (*p*-hydroxyphenylacetic acid)	C T M	0.27 (0.05-0.53) 0.41 (0.35-0.52) 0.40 (0.07-0.93)	(9)
3′,4′-dihydroxyphenylacetic acid (dopac)	M	277 [c]	(2)[f]
	M	R.Q.	(44)
4′-hydroxy-3′-methoxyphenylacetic acid (homovanillic acid)	M	R.Q.	(44)
3′-hydroxy-4′-methoxyphenylacetic acid (Isohomovanillic acid)	M	R.Q.	(44)
5-(phenyl)-γ-valerolactone			
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-glucuronide (isomer 1) [b]	M	26	(40)
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-glucuronide (isomer 2) [b]	C T M	37 (22-39) (19-39)	(40)
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-sulfate	C T M	(165-781) (24-1909) (20-435)	(40)
5-(3′-methoxyphenyl)-γ-valerolactone-4′-glucuronide	M	24	(40)
5-(3′-methoxy-4′-hydroxyphenyl)-γ-valerolactone-sulfate [e]	T M	(14-26) (17-20)	(40)
5-(3′-methoxy-4′-hydroxyphenyl)-γ-valerolactone-sulfate [e]	C T M	20 20 17 (16.9-17.2)	(40)
5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone	M	R.Q.	(44)
5-(4′-hydroxyphenyl)-γ-valerolactone-3′-glucuronide	M	R.Q.	(44)
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-sulfate [b]	M	R.Q.	(44)
Hippuric Acids			
hippuric Acid	M	R.Q.	(44)
Chlorogenic acids			

chlorogenic acid	C	9.43 (0.57-26.82)	(9)
	T	17.72 (2.39-40.02)	
	M	1.03 (0.01-2.61)	

C- Colostrum, T- transitional milk, M- Mature Milk, R.Q.- Relative quantification

[a] The concentrations listed are the highest concentrations reported in each study or a range when more than one concentration is presented. Studies reporting only relative quantification are referred as R.Q (relative quantification).[b] The concentration reflects the sum of two possible isomers; [c] Highest reported concentration between the three experimental groups in the study (low, medium, and high (poly)phenol consumers); [d] Converted from µg/L to nmol/L; [e] The original manuscript states two sulfate isomers for "5-(3ᵉ-methoxy-4ᵉ-hydroxyphenyl)-γ-valerolactone-sulfate". However, this molecule only has one hydroxyl group available for sulfation. For this reason, it is possible that the isomers mentioned in the original manuscript are 5-(3ᵉ-methoxyphenyl)-γ-valerolactone-4ᵉ-sulfate and 5-(4ᵉ-methoxyphenyl)-γ-valerolactone-3ᵉ-sulfate.